4-Nov-2025 6:00 AM CST - Business Wire Exact Sciences to Participate in November Investor Conference Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Jefferies London Healthcare Conference, London Fireside chat on Tuesday, November 18, 2025 at 7:30 a.m. ET (12:30 p.m. GMT) The webcast can be accessed in the investor relations section of Exact Sciences website at www.exactsciences.c
3-Nov-2025 3:05 PM CST - Business Wire Exact Sciences Announces Third Quarter 2025 Results Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $851 million for the third quarter ended September 30, 2025, compared to $709 million for the same period of 2024. Exact Sciences continues to advance our mission to prevent cancer and detect it earlier through a relentless focus on patients, said Kevin Conroy, chairman and CEO. Our third quarter results reflec
8-Oct-2025 6:00 AM CST - Business Wire Exact Sciences Schedules Third Quarter 2025 Earnings Call Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2025 financial results after the close of the U.S. financial markets on November 3, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2025 webcast & conference call details Date: M
19-Aug-2025 5:00 AM CST - Business Wire Exact Sciences to Participate in September Investor Conferences Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Wells Fargo Healthcare Conference, Boston Fireside chat on Wednesday, September 3, 2025 at 1:30 p.m. ET Baird Global Healthcare Conference, New York Fireside chat on Tuesday, September 9, 2025 at 10:50 a.m. ET The webcast can be acces
6-Aug-2025 3:05 PM CST - Business Wire Exact Sciences Announces Second Quarter 2025 Results Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $811 million for the second quarter ended June 30, 2025, compared to $699 million for the same period of 2024. The Exact Sciences team continues to build momentum, advancing our mission through earlier detection, said Kevin Conroy, chairman and CEO. In the second quarter, we delivered answers to more patients t
14-Jul-2025 5:00 AM CST - Business Wire Exact Sciences Schedules Second Quarter 2025 Earnings Call Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details Date: W
27-May-2025 3:05 PM CST - Business Wire Exact Sciences to Participate in June Investor Conference Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. William Blair 45th Annual Growth Stock Conference, Chicago Presentation on Tuesday, June 3, 2025 at 9:40 a.m. ET The webcast can be accessed in the investor relations section of Exact Sciences website at www.exactsciences.com. About E
2-May-2025 5:00 AM CST - Business Wire Exact Sciences to Participate in May Investor Conference Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences website at www.exactsciences.co
1-May-2025 3:05 PM CST - Business Wire Exact Sciences Announces First-Quarter 2025 Results Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended March 31, 2025, compared to $638 million for the same period of 2024. Our strong first quarter results pave the way for 2025 to mark our most transformative year yet, said Kevin Conroy, chairman and CEO. The Exact Sciences team just launched two innovative tests: Cologua
Latest EXAS Trades by Congress Members
10-MAY-2024 - Josh Gottheimer, NJ (District 5) sold between $1,001 and $15,000.
4-Nov-2025 6:00 AM CST - Business Wire Exact Sciences to Participate in November Investor Conference Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Jefferies London Healthcare Conference, London Fireside chat on Tuesday, November 18, 2025 at 7:30 a.m. ET (12:30 p.m. GMT) The webcast can be accessed in the investor relations section of Exact Sciences website at www.exactsciences.c
3-Nov-2025 3:05 PM CST - Business Wire Exact Sciences Announces Third Quarter 2025 Results Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $851 million for the third quarter ended September 30, 2025, compared to $709 million for the same period of 2024. Exact Sciences continues to advance our mission to prevent cancer and detect it earlier through a relentless focus on patients, said Kevin Conroy, chairman and CEO. Our third quarter results reflec
8-Oct-2025 6:00 AM CST - Business Wire Exact Sciences Schedules Third Quarter 2025 Earnings Call Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2025 financial results after the close of the U.S. financial markets on November 3, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2025 webcast & conference call details Date: M
19-Aug-2025 5:00 AM CST - Business Wire Exact Sciences to Participate in September Investor Conferences Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Wells Fargo Healthcare Conference, Boston Fireside chat on Wednesday, September 3, 2025 at 1:30 p.m. ET Baird Global Healthcare Conference, New York Fireside chat on Tuesday, September 9, 2025 at 10:50 a.m. ET The webcast can be acces
6-Aug-2025 3:05 PM CST - Business Wire Exact Sciences Announces Second Quarter 2025 Results Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $811 million for the second quarter ended June 30, 2025, compared to $699 million for the same period of 2024. The Exact Sciences team continues to build momentum, advancing our mission through earlier detection, said Kevin Conroy, chairman and CEO. In the second quarter, we delivered answers to more patients t
14-Jul-2025 5:00 AM CST - Business Wire Exact Sciences Schedules Second Quarter 2025 Earnings Call Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details Date: W
27-May-2025 3:05 PM CST - Business Wire Exact Sciences to Participate in June Investor Conference Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. William Blair 45th Annual Growth Stock Conference, Chicago Presentation on Tuesday, June 3, 2025 at 9:40 a.m. ET The webcast can be accessed in the investor relations section of Exact Sciences website at www.exactsciences.com. About E
2-May-2025 5:00 AM CST - Business Wire Exact Sciences to Participate in May Investor Conference Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences website at www.exactsciences.co
1-May-2025 3:05 PM CST - Business Wire Exact Sciences Announces First-Quarter 2025 Results Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended March 31, 2025, compared to $638 million for the same period of 2024. Our strong first quarter results pave the way for 2025 to mark our most transformative year yet, said Kevin Conroy, chairman and CEO. The Exact Sciences team just launched two innovative tests: Cologua
